According to the National Cancer Institute, more than 21,000 Americans are diagnosed with multiple myeloma and 10,710 die from the disease annually. It is the second most common hematologic cancer after non-Hodgkin's lymphoma, accounting for approximately 1 percent of all cancers in the U.S. Several new therapies have received FDA approval recently and they appear to work well in combination with existing treatments.